In November 2022, OmniAb completed a strategic spin-off from Ligand Pharmaceuticals, a long-time Curran & Connors client. As a newly independent company, OmniAb needed to quickly establish a distinct and cohesive brand identity. While they had an existing logo, they turned to C&C to develop comprehensive brand standards and implement them consistently across all touchpoints—helping translate their scientific innovation into a professional and impactful visual language.
Recognizing the urgency and scope of the task, C&C quickly became a trusted extension of OmniAb’s marketing team. Over the last few years, we collaborated on a wide range of projects, all designed to bring structure, clarity, and credibility to the brand. This included the development of a style guide, PowerPoint templates, business systems, marketing collateral, event signage, giveaways, email campaigns, and high-quality print production. Each deliverable was crafted with intention, aligned with the evolving brand standards, and tailored to support OmniAb’s communications across a range of audiences—from investors to research partners.
The results went far beyond visual refinement. Our consistent and strategic design support gave OmniAb the tools to show up with confidence in the marketplace, elevating their visibility and credibility as a leader in antibody discovery. The partnership stands as an example of how a collaborative, integrated approach can support a successful corporate transition and lay the groundwork for a strong, enduring brand.
